R & D

Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

This material is intended to notify that Fate Therapeutics, Inc., our alliance partner for ONO-8250, issued a press release regarding FT825/ONO-8250 on January 8 (local time).

Please refer to the following link below for the original press release issued by Fate Therapeutics: